百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688506 百利天恒

交易中 07-11 13:24:12

{"stockData":{"symbol":"688506","market":"SH","secType":"STK","nameCN":"百利天恒","latestPrice":287.12,"timestamp":1752211452000,"preClose":285,"halted":0,"volume":552745,"delay":0,"changeRate":0.0074,"floatShares":103000000,"shares":401000000,"eps":-4.5614,"marketStatus":"交易中","change":2.12,"latestTime":"07-11 13:24:12","open":285.58,"high":293,"low":284.08,"amount":160000000,"amplitude":0.0313,"askPrice":287.14,"askSize":6,"bidPrice":287.12,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-4.5614,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1752217200000},"marketStatusCode":2,"adr":0,"adjPreClose":285,"symbolType":"stock_kcb","openAndCloseTimeList":[[1752197400000,1752204600000],[1752210000000,1752217200000]],"highLimit":313.5,"lowLimit":256.5,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":401000000,"isCdr":false,"pbRate":33.9,"roa":"--","roe":"--","epsLYR":9.25,"committee":0.5,"marketValue":115135000000,"turnoverRate":0.0054,"status":0,"floatMarketCap":29542000000},"requestUrl":"/m/hq/s/688506","defaultTab":"news","newsList":[{"id":"2550753376","title":"百利天恒股价小幅回落 科创板百元股溢价超10倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2550753376","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550753376?lang=zh_cn&edition=full","pubTime":"2025-07-11 03:33","pubTimestamp":1752176001,"startTime":"0","endTime":"0","summary":"截至2025年7月10日收盘，百利天恒股价报285.00元，较前一交易日下跌1.95%，成交额2.70亿元。当日开盘价为290.00元，盘中最高触及293.42元，最低下探284.00元，振幅3.24%。百利天恒属于医药生物行业，专注于创新药研发与生产，是科创板高价股之一。公司最新总市值达1142.85亿元，流通市值293.24亿元。数据显示，百利天恒最新收盘价较发行价溢价1053.85%，在科创板百元股中溢价幅度居前。此外，2025年7月10日主力资金净流入1410.75万元。风险提示：股市有风险，投资需谨慎。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071103402097a150a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071103402097a150a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","159982","688506"],"gpt_icon":0},{"id":"2550468586","title":"沪深300制药指数报11609.22点，前十大权重包含百利天恒等","url":"https://stock-news.laohu8.com/highlight/detail?id=2550468586","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550468586?lang=zh_cn&edition=full","pubTime":"2025-07-09 15:16","pubTimestamp":1752045410,"startTime":"0","endTime":"0","summary":"金融界7月9日消息，A股三大指数收盘涨跌不一，沪深300制药指数 报11609.22点。数据统计显示，沪深300制药指数近一个月下跌2.48%，近三个月上涨5.29%，年至今上涨6.57%。据了解，沪深300制药指数从沪深300指数中选取与制药主题相对应的行业内上市公司证券作为指数样本，以反映该主题上市公司证券的整体表现。该指数以2004年12月31日为基日，以1000.0点为基点。从沪深300制药指数持仓样本的行业来看，药品制剂占比63.81%、中成药占比30.31%、原料药占比5.88%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709152309979f5935&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709152309979f5935&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159919","000001.SH","688506","BK0239","399300"],"gpt_icon":0},{"id":"2549964455","title":"百利天恒BL-B01D1更新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2549964455","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549964455?lang=zh_cn&edition=full","pubTime":"2025-07-08 11:24","pubTimestamp":1751945052,"startTime":"0","endTime":"0","summary":"近日，百利天恒自主研发的全球首创双抗ADC药物BL-B01D1在治疗局部晚期或转移性鼻咽癌的III期临床试验中取得了重大进展。百利天恒的BL-B01D1正是在这一背景下应运而生，它以其独特的创新药物机制，为鼻咽癌治疗带来了新的思路。分析结果显示，BL-B01D1在这些关键指标上均达到了预期目标，显示出显著的疗效和良好的安全性。值得一提的是，BL-B01D1的国际化进程也在稳步推进。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708112626a69c3114&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708112626a69c3114&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688506","BK0239"],"gpt_icon":0},{"id":"2549781598","title":"百利天恒股价下跌3.10% 利空情绪引发资金分歧","url":"https://stock-news.laohu8.com/highlight/detail?id=2549781598","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549781598?lang=zh_cn&edition=full","pubTime":"2025-07-08 10:24","pubTimestamp":1751941463,"startTime":"0","endTime":"0","summary":"百利天恒股价大幅下跌，最新价293.50元/股，跌幅3.10%。资金博弈与政策预期共振百利天恒近期股价波动受多重事件催化。板块层面，截至7月3日，科创50指数近五日累计上涨4.36%，医药生物板块估值修复吸引资金调仓。截至7月7日，主力资金累计净流入1293.8万元，较前一日回落，显示资金分歧加大。但传统业务受集采冲击显著，2025年前三季度营收同比下滑98.77%至6700万元，亏损5.31亿元凸显盈利压力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708102428a69c1242&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708102428a69c1242&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688506"],"gpt_icon":0},{"id":"2549733538","title":"药企纷纷角逐双抗ADC，这家国内企业突出重围","url":"https://stock-news.laohu8.com/highlight/detail?id=2549733538","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549733538?lang=zh_cn&edition=full","pubTime":"2025-07-07 14:56","pubTimestamp":1751871418,"startTime":"0","endTime":"0","summary":"目前，全球范围内布局双抗 ADC 的药企不在少数，竞争日益激烈。从市场前景来看，双抗 ADC 潜力巨大。随着癌症发病率的上升以及患者对更有效治疗方案的迫切需求，双抗 ADC 有望在肿瘤治疗领域占据重要地位。未来，随着更多药企的加入、技术的持续创新，双抗 ADC 有望掀起癌症治疗领域的新革命，为全球癌症患者带来更多生的希望。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070715000895393956&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070715000895393956&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688506","BK0239"],"gpt_icon":0},{"id":"2549328628","title":"突破双抗ADC首个！当百利天恒从双抗ADC中杀出重围","url":"https://stock-news.laohu8.com/highlight/detail?id=2549328628","media":"药渡","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549328628?lang=zh_cn&edition=full","pubTime":"2025-07-06 07:30","pubTimestamp":1751758235,"startTime":"0","endTime":"0","summary":"百利天恒在寻找新的公式解法——双抗ADC，而令人惊喜的是，真的实现了全球首个的突破。这是全球首个完成III期研究并达到主要终点的双抗ADC。截至目前，BL-B01D1已有5项适应症被CDE纳入突破性治疗品种名单。关于双抗ADC的竞争格局根据药渡数据库，目前全球有多款双抗ADC在研，其中正大天晴的HER2双表位ADC药物TQB2102也正处于III期研究，在今年ASCO大会上，中国生物制药公布了TQB2102的II期临床数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250706073341a4390c46&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250706073341a4390c46&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688506"],"gpt_icon":0},{"id":"2549344719","title":"每周股票复盘：百利天恒（688506）iza-bren三期临床期中分析达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2549344719","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549344719?lang=zh_cn&edition=full","pubTime":"2025-07-06 02:23","pubTimestamp":1751739790,"startTime":"0","endTime":"0","summary":"截至2025年7月4日收盘，百利天恒报收于307.15元，较上周的297.39元上涨3.28%。本周，百利天恒7月4日盘中最高价报316.33元。本周关注点公司公告汇总：百利天恒药业iza-bren三期临床试验期中分析达到主要终点公司公告汇总百利天恒药业股份有限公司宣布，其开发的iza-bren用于治疗局部晚期或转移性鼻咽癌的III期临床试验的期中分析已达到主要终点。此药物是全球首创且唯一进入III期临床阶段的EGFR×HER3双抗ADC。截至目前，iza-bren已有5项适应症被纳入突破性治疗品种名单。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070600000240.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688506"],"gpt_icon":0},{"id":"2548330540","title":"创新药板块逆势上行，机构称创新药为核心投资主线","url":"https://stock-news.laohu8.com/highlight/detail?id=2548330540","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548330540?lang=zh_cn&edition=full","pubTime":"2025-07-04 10:29","pubTimestamp":1751596152,"startTime":"0","endTime":"0","summary":"7月4日早盘，A股整体小幅回落，医药板块逆势上行，科创医药ETF基金涨幅超0.5%。公开信息显示，科创医药ETF基金跟踪上证科创板生物医药指数，囊括科创板中创新药、国产高端医疗设备、生命科学与生物技术等领域的专精特新公司。伴随政策对创新药保驾护航、创新药获批上市井喷、出海以及国产替代，医药行业有望迎来机会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704103134a4ce73ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704103134a4ce73ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688506","688076","159992","688520","688331","688505","688091"],"gpt_icon":0},{"id":"2548334105","title":"百利天恒涨3.02% 创新药研发预期升温带动股价走强","url":"https://stock-news.laohu8.com/highlight/detail?id=2548334105","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548334105?lang=zh_cn&edition=full","pubTime":"2025-07-04 09:38","pubTimestamp":1751593131,"startTime":"0","endTime":"0","summary":"百利天恒股价今日大幅上涨，截至09点38分，最新价报307.00元，涨幅达3.02%，突破300元整数关口。资金博弈与政策预期共振百利天恒近期股价波动与资金面变化密切相关。截至7月2日，主力资金连续七日累计净流入超1.1亿元，其中6月30日单日净流入达1961万元，显示机构对创新药管线的关注度提升。技术转化效率决定估值重构空间百利天恒长期价值锚定在研药物商业化进展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704093853a4ce580e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704093853a4ce580e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688506","BK0239","159992"],"gpt_icon":0},{"id":"2548017333","title":"私募6月调研青睐电子和医药  迈威生物获调研超50次","url":"https://stock-news.laohu8.com/highlight/detail?id=2548017333","media":"投资快报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548017333?lang=zh_cn&edition=full","pubTime":"2025-07-04 07:26","pubTimestamp":1751585168,"startTime":"0","endTime":"0","summary":"迈威生物6月获得私募调研51次，成为最受私募调研青睐的个股，该股属于医药生物行业，吸引到高毅资产、海南希瓦、聚鸣投资、宁泉资产、盘京投资、中欧瑞博、重阳投资等百亿私募扎堆调研。正圆投资调研最为积极，6月调研35次居首。6月共有31家百亿私募参与到A股调研，合计调研达176次。其次是高毅资产、睿郡资产、和谐汇一资产、重阳投资、宁泉资产等10家百亿私募，6月调研次数均不少于5次。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704072908a72d75b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704072908a72d75b9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159938","688506","688062","BK0239"],"gpt_icon":0},{"id":"2548789885","title":"百利天恒：iza-bren在治疗鼻咽癌的III期临床试验中期中分析达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2548789885","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548789885?lang=zh_cn&edition=full","pubTime":"2025-07-02 17:41","pubTimestamp":1751449305,"startTime":"0","endTime":"0","summary":"蓝鲸新闻7月2日电，百利天恒(688506.SH)公告称，公司自主研发的全球首创EGFR×HER3双抗ADC药物iza-bren在鼻咽癌的III期临床试验中期中分析达到主要终点，适应症为既往经PD-1/PD-L1单抗治疗且经至少两线化疗（至少一线含铂）治疗失败的复发性或转移性鼻咽癌。该药物目前在中国和美国进行40余项针对多种肿瘤类型的临床试验，已有5项适应症被纳入突破性治疗品种名单。但需注意，药品从临床试验到投产周期长，存在不确定性因素影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507021743069533c14d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507021743069533c14d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688506"],"gpt_icon":0},{"id":"2548830744","title":"百利天恒股价下跌3.14% 医药生物板块估值修复未改短期资金流出压力","url":"https://stock-news.laohu8.com/highlight/detail?id=2548830744","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548830744?lang=zh_cn&edition=full","pubTime":"2025-07-02 10:12","pubTimestamp":1751422348,"startTime":"0","endTime":"0","summary":"百利天恒股价大幅下跌，最新价292.54元，跌幅3.14%。资金情绪与事件催化共振百利天恒近期股价波动与多重短期因素交织。截至6月30日，该股连续四日主力资金累计净流入超4000万元，但7月2日早盘出现资金转向，主力净流出3369万元引发股价振幅达4.42%。板块层面，医药生物板块估值修复形成助推，科创50指数近五个交易日上涨4.36%，为创新药标的创造了交易窗口。技术转化与业绩验证双重考验创新药研发进展与商业化能力构成百利天恒长期价值核心。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702101229a4ca0cba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702101229a4ca0cba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688506","163118","BK0239","000808.SH"],"gpt_icon":0},{"id":"2548046015","title":"自免 TCE 风起云涌，中国 Biotech 差异化布局领跑全球","url":"https://stock-news.laohu8.com/highlight/detail?id=2548046015","media":"医麦客","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548046015?lang=zh_cn&edition=full","pubTime":"2025-07-01 07:20","pubTimestamp":1751325625,"startTime":"0","endTime":"0","summary":"公开数据显示，目前全球已有约 10 款 TCE 疗法获批上市，主要覆盖血液瘤与实体瘤两大领域，靶点包括 CD19、CD20、BCMA 和 GPRC5D 等。国产自免 TCE 出海潮四家 CD3/BCMA 各有千秋近一年来，MNC 在自免领域的管线争夺趋于白热化。此前，PIT565 已在国内获批临床，拟用于治疗 B 细胞恶性肿瘤。目前，PIT565 针对 B 细胞恶性肿瘤和系统性红斑狼疮两种适应症均处于 1 期临床。CC312是惠和生物基于其新一代共刺激信号 TCE 平台 TriTETM自主研发的CD19/CD3/CD28 三抗，也是全球首个获批系统性","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701072710a4c779eb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701072710a4c779eb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02142","688443","688506","02162","BK0239"],"gpt_icon":0},{"id":"2547015164","title":"中国创新药能否持续让世界买单？券商分析师最新观点","url":"https://stock-news.laohu8.com/highlight/detail?id=2547015164","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547015164?lang=zh_cn&edition=full","pubTime":"2025-06-30 23:29","pubTimestamp":1751297340,"startTime":"0","endTime":"0","summary":"医药魔方统计，2025年1—5月，中国创新药企对外授权交易总金额已达455亿美元，超过2024年上半年的交易总额，创新药出海授权交易大爆发。亮眼数据的背后，是中国创新药整体水平的强势崛起。“中国创新药产业的研发、临床与生产能力，正处于与国际一线水平接轨的初始阶段。”由于BD数据不及预期，年内大涨明显的创新药企业荣昌生物股价近期大幅回调，从而带动创新药板块整体调整。华泰柏瑞恒生创新药ETF6月中旬以来一度单周下行超过8%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630233154a7267585&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630233154a7267585&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["601089","601607","688336","600332","603127","06160","600196","600422","688163","600998","688222","600062","600521","600380","603590","688166","600682","600867","688177","688235","688513","600200","159992","688321","600222","603229","603259","600080","603716","600645","603087","600216","600557","603367","688488","600572","603707","600774","688136","BK0239","600513","688198","600789","603567","600079","ONC","600851","600881","603456","600420","688331","605199","600351","688356","600535","688091","688505","688317","600276","688068","688202","688319","688506","688181","688189","688278","603998","688520","688117","600267","688131","600056","600721","688073"],"gpt_icon":0},{"id":"2547962950","title":"从盈利37亿元到亏损5.3亿元，百利天恒的“一次性收入”游戏还能玩多久","url":"https://stock-news.laohu8.com/highlight/detail?id=2547962950","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547962950?lang=zh_cn&edition=full","pubTime":"2025-06-30 19:36","pubTimestamp":1751283392,"startTime":"0","endTime":"0","summary":"2025年第一季度，公司营收仅约6700万元，同比暴跌98.77%；同期净利润亏损5.31亿元。传统业务表现不佳事实上，百利天恒传统业务收入一直在萎缩。据披露，近年来，百利天恒的收入结构主要分为化药制剂和中成药制剂两大类别，其中化药制剂又包含多个具体产品。2022年至2024年，百利天恒研发费用占营业收入的比例分别为53.32%、132.81%和24.78%，整体研发费用占营业收入的比例为36.18%。百利天恒当前正面临业绩波动剧烈、传统业务持续萎缩与研发创新不足的多重挑战。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025063019410495313509&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025063019410495313509&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688506"],"gpt_icon":0},{"id":"2546799257","title":"认定标准不一！百利天恒8亿美元首付款计入经常性损益引争议","url":"https://stock-news.laohu8.com/highlight/detail?id=2546799257","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546799257?lang=zh_cn&edition=full","pubTime":"2025-06-27 15:01","pubTimestamp":1751007660,"startTime":"0","endTime":"0","summary":"2024年，百时美施贵宝公司向百利天恒支付了首付款8亿美元，使得百利天恒业绩大增，亦在市场上引来诸多疑问。表面看，百利天恒2024年经营业绩已然是属于较为成熟、经营收入稳定、具有一定规模的药企，更显示出一次性首付款收入的特殊性。认定标准不一尽管百利天恒将BMS授权收入一次性计入营业收入，但是在定增报告中公司却自行进行了剔除调整处理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627150236952db4a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627150236952db4a0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688506","BK0239"],"gpt_icon":0},{"id":"2546879607","title":"创新药融资环境逐步回暖，头部药企再融资动作频频！","url":"https://stock-news.laohu8.com/highlight/detail?id=2546879607","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546879607?lang=zh_cn&edition=full","pubTime":"2025-06-27 14:45","pubTimestamp":1751006746,"startTime":"0","endTime":"0","summary":"近期以来，随着创新药融资环境逐步回暖，头部药企再现融资动作。根据信达生物公告，本次配售股份的数目相当于该公告披露日公司已发行股份总数的约3.33%；配售价则相当于信达生物股份于6月25日在联交所所报的收市价每股82.4港元折让约4.90%。因此，董事认为，配售事项符合本集团及股东的整体利益。除了信达生物外，君实生物、百利天恒等多家创新药企也纷纷启动配售新股、定增等再融资举措。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506271447599790f502&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506271447599790f502&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688180","01877","162717","159992","BK0239","688506"],"gpt_icon":0},{"id":"2546273983","title":"百利天恒早盘下挫3%破300元线 研发高投入加剧亏损风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2546273983","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546273983?lang=zh_cn&edition=full","pubTime":"2025-06-26 09:38","pubTimestamp":1750901924,"startTime":"0","endTime":"0","summary":"百利天恒早盘股价大幅下挫，截至09点38分，下跌3.03%，报289.85元/股。股价异动催化因素百利天恒近期股价波动显著，突破300元关口，短期驱动因素多元。同时，6月20日披露的募资计划提振信心，拟募资37.64亿元用于创新药研发，吸引投资者关注。板块联动效应明显，科创板50指数近期上涨，ETF资金连续净流入，带动医药生物板块整体走强。资金面显示积极信号，截至6月23日主力资金累计净流入1294万元，反映短期买盘活跃。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626093850a71df295&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626093850a71df295&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688506","BK0239"],"gpt_icon":0},{"id":"2546803210","title":"百利天恒，世界级MNC的潜质","url":"https://stock-news.laohu8.com/highlight/detail?id=2546803210","media":"市值观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546803210?lang=zh_cn&edition=full","pubTime":"2025-06-25 20:01","pubTimestamp":1750852913,"startTime":"0","endTime":"0","summary":"2014年，当百利天恒在美国西雅图设立SystImmune时，外界恐怕不会预想到，十年后，它将成为全球ADC领域耀眼的后起之秀。百利天恒堪称中国创新药产业历史征程的一面旗帜。与国内同侪相比，百利天恒拥有中美两地研发平台，多个FIC药物已经证实其不俗的研发实力。03全球基因，扬帆海外不同于国内其他创新药企业，百利天恒自转型之日起，就带有全球化的基因。全球合作方面，百利天恒更是业界领头羊。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625202516a4bd5a06&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625202516a4bd5a06&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688506"],"gpt_icon":0},{"id":"2545402622","title":"百利天恒06月24日主力净流出314.8万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2545402622","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545402622?lang=zh_cn&edition=full","pubTime":"2025-06-24 15:20","pubTimestamp":1750749655,"startTime":"0","endTime":"0","summary":"06月24日, 百利天恒股价跌0.25%，报收293.29元，成交金额2.4亿元，换手率0.80%，振幅2.14%，量比0.87。百利天恒今日主力资金净流出314.8万元，上一交易日主力净流入1926.3万元。该股近5个交易日下跌4.47%，主力资金累计净流出1661.2万元；近20日主力资金累计净流入5894.1万元，其中净流入天数为12日。|06月24日主力加仓幅度排名||#|股票简称|主力净额占比|#|华铭智能|7.31%|#|星源卓镁|6.19%|#|信德新材|6.16%|#|...|...|#3115|百利天恒|-0.01%|百利天恒所在的化学制药行业，今日主力净流入5746万元，行业排名55/124。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624170005a71ae8bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624170005a71ae8bf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688506"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1752211453150,"stockEarnings":[{"period":"1week","weight":-0.0436},{"period":"1month","weight":-0.1573},{"period":"3month","weight":0.1671},{"period":"6month","weight":0.5869},{"period":"1year","weight":0.6673},{"period":"ytd","weight":0.4865}],"compareEarnings":[{"period":"1week","weight":0.014},{"period":"1month","weight":0.0369},{"period":"3month","weight":0.0838},{"period":"6month","weight":0.1077},{"period":"1year","weight":0.194},{"period":"ytd","weight":0.0471}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"四川百利天恒药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"4585人(较上一季度减少1.12%)","perCapita":"22440股","listingDate":"2023-01-06","address":"四川省成都市温江区成都海峡两岸科技产业园百利路161号一幢一号","registeredCapital":"40100万元","survey":"　　四川百利天恒药业股份有限公司的主营业务是创新生物药业务板块和化药制剂、中成药制剂业务板块。公司的主要产品是丙泊酚乳状注射液、丙泊酚中/长链脂肪乳注射液、吸入用七氟烷、中/长链脂肪乳注射液、结构脂肪乳注射液(C6~24)、黄芪颗粒、盐酸胍法辛缓释片。","listedPrice":24.7},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百利天恒,688506,百利天恒股票,百利天恒股票老虎,百利天恒股票老虎国际,百利天恒行情,百利天恒股票行情,百利天恒股价,百利天恒股市,百利天恒股票价格,百利天恒股票交易,百利天恒股票购买,百利天恒股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}